134TiP A phase I/II study of nanoliposomal irinotecan plus S-1 in metastatic pancreatic cancer after first-line gemcitabine-based chemotherapy

Abstract

S-1, an oral fluoropyrimidine anticancer drug, showed promising results in patients with unresectable pancreatic cancer (PC) in a phase 3 study (Ueno, 2013). Thus, the nanoliposomal irinotecan (nal-IRI)/S-1 regimen, replacing 5-FU/LV in the nal-IRI+5-FU/LV regimen with S-1, not only improves the convenience of treatment with no requirement of intravenous port system, but it is also expected to exert stronger anticancer effects. Thus, a phase 1/2 study to evaluate the safety and efficacy of nal-IRI/S-1 for the treatment of metastatic PC after previous gemcitabine-based chemotherapy was conducted.